ARTICLE | Financial News
Tarsus targets mites driving inflammatory eye disease with $60M series B
January 8, 2020 8:45 PM UTC
Updated on Jan 9, 2020 at 12:36 AM UTC
Tarsus thinks its topical therapy against the parasite behind nearly half of blepharitis cases could become the first drug approved for the ophthalmic disease.
The company's $60 million series B round, announced Wednesday, was led by Vivo Capital and included Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners and Horowitz Group. ...